Because the NFAT1-MDM2 signaling pathway has been implicated in prostate cancer cell proliferation and apoptosis (Li et al., 2005; Zhang et al., 2012), it was hypothesized that targeting the NFAT1–MDM2 interaction could represent a potential therapeutic strategy for prostate cancer. Here, MDM2 is linked to prostate carcinoma.